Relative thromboembolic risks associated with COX-2 inhibitors (Q30437125)

21 June 2017

0 references

1 reference

title

Relative thromboembolic risks associated with COX-2 inhibitors (English)

1 reference

21 June 2017

1 reference

S Christopher Jones

1

1 reference

21 June 2017

language of work or name

English

0 references

publication date

14 June 2005

1 reference

Annals of Pharmacotherapy

21 June 2017

published in

1 reference

21 June 2017

volume

39

1 reference

21 June 2017

issue

7-8

1 reference

21 June 2017

page(s)

1249-1259

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 June 2017

cites work

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

21 January 2018

1 reference

Coxibs and cardiovascular disease

21 January 2018

1 reference

Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?

21 January 2018

1 reference

Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?

21 January 2018

1 reference

New look at myocardial infarction: toward a better aspirin

21 January 2018

1 reference

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data

21 January 2018

1 reference

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data

21 January 2018

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

Parecoxib (parecoxib sodium).

21 January 2018

1 reference

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

21 January 2018

1 reference

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

21 January 2018

1 reference

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

21 January 2018

1 reference

Selective cyclooxygenase-2 inhibitors: similarities and differences

21 January 2018

1 reference

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

21 January 2018

1 reference

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

Raising the safety bar--the FDA's coxib meeting

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E654

1 reference

release_fhxmigg5cndylnk7b7ytpj2r64

21 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fhxmigg5cndylnk7b7ytpj2r64

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference